BioSpace

Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug

The go-ahead for Alnylam Pharmaceuticals–licensed Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.

By BioSpace

1 min read
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights